Health Care • Ophthalmic Goods
$24.59 ▲ +0.16
(+0.66%)
MKT CAP: $3.04B • VOL: 2.60M
52W L $15 52W H $31
WRBY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $871.9M | $771.3M | $669.8M |
| YoY Revenue Growth % | +13.0% | +15.2% | — |
| Gross Profit | $470.6M | $426.8M | $294.7M |
| Gross Margin % | 54.0% | 55.3% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.3M | -$30.1M | -$72.0M |
| Operating Margin % | -0.6% | -3.9% | -10.7% |
| Net Income (GAAP) | $1.6M | -$20.4M | -$63.2M |
| EBITDA (Normalized) | $48.3M | $21.1M | -$47.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $110.8M | $98.7M | $61.0M |
| Capital Expenditures (CapEx) | $67.0M | $64.0M | $30.1M |
| Free Cash Flow (FCF) | $43.7M | $34.7M | $30.9M |
| FCF Margin % | 5.0% | 4.5% | 4.6% |
| Return on Invested Capital (ROIC %) | -1.8% | -10.0% | -5.6% |
| Cash & Short-Term Equivalents | $286.4M | $254.2M | $183.9M |
| Total Debt (Short + Long Term) | $158.9M | $151.4M | $391.2M |
| Total Stockholders' Equity | $367.7M | $340.1M | $802.4M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR WRBY.